PHPC COVID-19 Vaccination : Phase 2 Onboarding - Engagement with PHPCs Saturday, 17 July 2021, 2pm - 3.30pm - Primary ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
PHPC COVID-19 Vaccination : Phase 2 Onboarding Engagement with PHPCs Saturday, 17 July 2021, 2pm – 3.30pm
Agenda
S/N Item Presenter Time
0 Opening remarks Deputy Director of Medical Services 5 mins
(Health Services Group), A/Prof Dan
Yock Young
1 Sharing of Best practices and Experience Dr Leong Choon Kit and Dr Loke Kam 10 mins
Weng
2 Introduction – Role of PHPCs in National COVID-19 Vaccination PCC 5 mins
Programme
3 Clinical and Ops Processes 30 mins
i. Requirements for PHPCs and support provided PCC
ii. Clinical Guidance (including vaccine preparation) PCC
iii. Vaccine Planning and Ordering SRMD
iv. Reporting Requirements CSOG
v. Other Ops Requirements AIC
4 Demo of PRPP IHiS 30 mins
5 Q&A Dr Ruth Lim, D(PCC), MOH 10 mins
Mr Gregory Foo, D(P&P), MOH
Ms Sylvia Wong, D, IHIS
Mr Jui Sheng Choo, DD(PC), AIC
Mr Anthony Loke, SAD(SRMD), MOH
2
Part 1 Sharing of Best Practices and Experience [Dr Leong Choon Kit and Dr Loke Kam Weng]
PART 2 INTRODUCTION [PCC]
PCC
PHPCs play an important role in national vaccination program
22 PHPCs stood up in
Jan 2021 to support
Administered more
national COVID-19
than 6.3mil doses of
efforts, alongside
the COVID-19 vaccine
vaccination centres
and polyclinics
5
PCC
PHPCs play an important role in national vaccination program
Persuade seniors who
are regular patients
Step up vaccination
First line of care in to go for COVID-19
efforts with another
the community vaccination, if
22 PHPCs
medically eligible but
not already done so
6
PCC
Phase 1: 22 PHPCs from our PCNs supported COVID-19 Vaccination with an
overall throughput of >600 per day. 22 more being set-up.
S/N PCN Clinic Name
1 NUHS PCN A MEDICAL CLINIC
2 ASSURANCE PCN ACUMED MEDICAL GROUP
3 ASSURANCE PCN ACUMED MEDICAL GROUP
4 FRONTIER PCN BEDOK MEDICAL CENTRE
5 UNITED PCN DAYSPRING MEDICAL CLINIC (TAMPINES)
6 CENTRAL-NORTH PCN EXCEL FAMILY CLINIC
7 SINGHEALTH DOT PCN FRASER MEDICAL CENTRE
8 CLASS PCN HK FAMILY CLINIC & SURGERY PTE LTD
9 SINGHEALTH DOT PCN JOY FAMILY CLINIC
10 UNITED PCN NORTHEAST MEDICAL GROUP
11 SINGHEALTH REG PCN ONECARE CLINIC YISHUN
12 SINGHEALTH REG PCN PANCARE MEDICAL CLINIC
13
PARKWAY SHENTON PCN PARKWAY SHENTON MEDICAL GROUP
14 RAFFLES MEDICAL PCN RAFFLESMEDICAL
15 RAFFLES MEDICAL PCN RAFFLESMEDICAL
16 CENTRAL-NORTH PCN SATA COMMHEALTH MEDICAL CENTRE
17 PARKWAY SHENTON PCN SHENTON MEDICAL GROUP
18 NUHS PCN TAYKA MEDICAL FAMILY CLINIC
19 I-CARE PCN THE TENTERAM CLINIC
20 CLASS PCN TRUCARE MEDICAL AND SURGERY
21 FRONTIER PCN YANG & YAP CLINIC AND SURGERY (PTE LTD)
22 SINGHEALTH DOT PCN YIM CLINIC
Legend:
In the coming months, we will be further ramping up more PHPCs to help reach Red: New Vacc Clinics
Blue: Existing Vacc Clinics
out to the population.
7
PART 3 Ops Processes [PCC, CSOG]
Part 3i Requirements for participating PHPCs and Support Provided [PCC]
PCC
General Requirements for clinics to come onboard as a COVID-19
Vaccination Clinic
1. Sufficient clinic space for holding vaccinees (we observed that most
clinics are holding about 12 vaccinees per session – to consider safe
distancing measures)
2. Doctors and/or clinic nurses providing vaccination must be BCLS
certified
3. Have IT hardware and stable internet connection to run MOH’s
designated IT application to support vaccination operations
4. Progressively achieve throughput of at least 24 vaccinees per day
5. Clinics are to be equipped with resuscitation equipment (e.g. oxygen
delivery system) and drugs (emergency kit)
10Part 3ii Clinical Guidance [PCC]
PCC
Clinics to be equipped with the following Resuscitation Equipment and
Emergency Medications
Mandatory
Medications 1. Adrenaline vial, pre-filled syringe or autoinjector*
2. Intravenous (IV) fluids
3. Antihistamines (H1 or H2 antagonists) (consider stocking syrup formulations as well)
4. IV Hydrocortisone
5. Inhaled bronchodilators (e.g. salbutamol) with appropriate delivery devices (e.g. spacer)
Equipment and Supplies 6. BP cuffs in small adult size and upwards
7. Stethoscope
8. IV drip set
9. IV cannulas in at least 2 different sizes most commonly used for small adults/adults
10. Manual resuscitator (e.g. Air Viva) – including at least 2 sizes of oro airways, starting with size 2
(70mm) and upwards
11. Pulse oximeter
12. Oxygen with delivery devices (e.g. face mask) in small adult size & upwards
*Clinician must be familiar with the IM adrenaline dosage (refer to MOH Circular 68/2021) for auto-injector and be able to administer it
promptly.
12PCC
Clinical guidance: Overview
1. Dosing information, contraindications and precautions
2. Vaccination preparation and administration
– Preparation: Dilution, administration, safety reminders
– Administration and post-vaccination care
3. Management of adverse reactions
– Anaphylaxis
– Adverse event reporting
4. Key takeaways
Reference/Credits: Slide content adapted from materials prepared by Dr Lim Poh Lian, NCID.
N.B. Please also refer to the latest MOH Circulars and guide to conducting COVID-19 vaccination at PHPCs for updated
vaccination guidance.
13PCC
1. Dosing information, contraindications, and precautions
Pfizer COVID-19 Vaccination: Dosing information
• The Pfizer COVID-19 vaccine dose contains: 30 mcg in 0.3 mL (post-dilution)
• 2 doses, given intramuscularly (IM), with a recommended dosing interval in 21 days (3
weeks), but can be taken with an interval of up to 6-8 weeks apart.
– Pfizer early 2nd dose: Considered valid from Day 17, no earlier
– Late 2nd dose: Give at earliest opportunity. No need to re-start vaccination, or repeat doses.
• Vaccine recipients should be counselled about importance of completing both doses in
the series.
– Both doses are necessary for full protection, and for long-lasting protection.
– 1 dose is not considered valid.
14PCC
Contraindications and precautions: Common scenarios
Category of patients Guidance
Allergy to prior dose of mRNA COVID vaccine or vaccine Do not vaccinate
components
Allergy or anaphylaxis to other vaccines Do not vaccinate, refer to allergist
Acute illness (e.g. pneumonia) Do not vaccinate, wait until recovered from acute illness.
Increased risk of haematoma with IM injections Can vaccinate with advice.
due to bleeding tendency Can vaccinate IM if patient accepts risk.
• On anti-coagulation There is no data to support SC injection.
• Bleeding disorders (haemophilia etc.) Advise to hold firm pressure at the injection site for at
• Low platelet counts (unless known to have platelets < least 5 minutes postvaccination.
50,000)
Fever (Temperature > 37.5C) in past 24 hours Defer vaccination until fever resolved. Offer ART and PCR
swab if indicated
Allergies or anaphylaxis to non-vaccine triggers (e.g. Allow vaccination
medications, food and insect stings, unknown triggers);
including individuals whoPlease
were refer
prescribed Epi-pen
to MOH Circulars for more details:
MOH Circular No. 66/2021 (“UPDATED GUIDANCE ON THE INDICATIONS
AND CONTRAINDICATIONS TO COVID-19 VACCINATION”)
15
MOH Circular No. 66A/2021 (Addendum to Circ No. 66/2021)PCC
Updated guidance on COVID-19 vaccinations
Category of patients Guidance
Severe Cutaneous Adverse Reactions Allow Vaccination^
• Stevens-Johnson Syndrome(SJS)
• Toxic Epidermal Necrolysis (TEN) ^ Updated guidance as of 31 May 2021. For more details, please
• Drug Rash with Eosinophilia and Systemic Symptoms refer to MOH Circular No. 66/2021 (UPDATED GUIDANCE ON THE
(DRESS) INDICATIONS AND CONTRAINDICATIONS TO COVID-19
VACCINATION).
• Drug-induced Hypersensitivity Syndrome (DiHS)
Active cancer on treatment Allow vaccination (in hospital setting)^
Breastfeeding Allow Vaccination^
Continue breastfeeding.
Pregnant women (any trimester) Allow Vaccination^
OR Can be vaccinated after patient discusses with her
Women who become pregnant after the first dose and obstetrician. Obstetrician memo not required, but
before second dose adequate documentation by vaccinator is advised.
Planning for conception Allow vaccination
Please refer to MOH Circular No. 66A/2021 for detailed guidance on:
• Groups recommended NOT for vaccination
• Groups who can be vaccinated with advice. 16PCC
Co-administration and interchangeability
Co-administration with other vaccines
• COVID-19 vaccines should be administered alone with a minimum interval of 14 days before/after
any other vaccines. No available data for safety or efficacy of the vaccine given simultaneously
with other vaccines.
• If inadvertently given within 14 days of another vaccine, no need to repeat doses for either vaccine.
Interchangeability
• No data on interchangeability of Pfizer with other COVID-19 vaccines. Encouraged to have both
doses completed with the same vaccine brand unless otherwise advised or arranged.
• If 2 doses of different mRNA vaccines are inadvertently given, no additional doses are
recommended.
17PCC Vaccinations for COVID-19 Recovered Persons • Individuals who have recovered from COVID-19 ≥ 6 months ago may receive a single dose of the COVID-19 vaccine • Criteria: 1. Positive SARS-CoV-2 PCR ≥ 6 months ago OR 2. Positive SARS-CoV-2 serology test result (without PCR results)
PCC
2. Vaccine preparation and administration Preparation and
Vaccine Preparation: BEFORE DILUTION administration
• Strict attention to aseptic technique must be
observed when accessing multi-dose vials
repeatedly.
• Gloves are not typically required when performing
vaccination.
• Take the vial out from the refrigerator to sit at
room temperature (up to 25ºC) for 30 minutes.
• Vials must reach room temperature before
dilution, and must be diluted within 2 hours.
• Before dilution, gently invert the vial 10 times.
• Do NOT shake vial.
19PCC
Preparation and
Vaccine Preparation: DILUTION (1)
administration
• Dilute the vial using 1.8 mL of 0.9% Sodium Chloride Injection to form the Pfizer-BioNTech/
Comirnaty COVID-19 vaccine.
• Use ONLY Sodium Chloride Injection 0.9%, USP as the diluent. This diluent is not
packaged with the vaccine.
• DO NOT use bacteriostatic 0.9% Sodium Chloride, or any other diluent.
• Using aseptic technique, withdraw 1.8 mL of diluent into a transfer syringe (with 21G or
narrower needle). Cleanse the vaccine vial stopper with a single use alcohol swab. Add 1.8
mL Sodium Chloride Injection into the vial.
• Before removing the needle from the vial, draw 1.8 mL of air into the syringe to equalize
pressure before withdrawing the needle.
• Gently invert the vial 10 times. DO NOT shake vial. Inspect the vial. Contents should be an
off-white suspension.
• Record the date & time of dilution on the vaccine vial. Store between 2ºC to 25ºC. Discard
any unused vaccine into a biohazard trash bag after 6 hours from dilution.
20PCC
Preparation and
Vaccine Preparation: DILUTION (2)
administration
21PCC
Preparation and
Post-Dilution Care
administration
• After dilution, store vials between 2°C to 25°C, and use within 6 hours
from time of dilution.
• Minimize exposure to room light, and avoid exposure to direct sunlight
and ultraviolet light.
• Any unused vaccine remaining in vials after dilution MUST be
discarded after 6 hours.
• DO NOT refreeze the vaccine.PCC
Preparation and
Safety Reminders
administration
• DO NOT administer the entire vial to a single patient.
• Each vial is a multi-dose vial which contains enough for 6 individuals
to be vaccinated.
• Strict attention to aseptic technique must be observed when accessing
multi-dose vials repeatedly.
• Use only a new single-dose syringe and needle to access the vial.PCC
Preparation and administration
Administering the Pfizer COVID-19 Vaccine For reference
• Review vaccination screening form for contraindications and precautions.
• Verify patient’s name, NRIC
• The patient should be seated when receiving the vaccine
• Do hand hygiene, and observe aseptic technique
• Cleanse the vial stopper with a single-use alcohol swab.
• Withdraw 0.3 mL of the Pfizer COVID-19 vaccine, using a 23G/25G needle.
• Visually inspect each dose in the dosing syringe prior to administration. The vaccine will be an off-
white suspension. Do not administer if vaccine is discolored or contains particulate matter.
• During the visual inspection, verify the final dosing volume of 0.3 mL
• Use an alcohol swab to clean the injection site.
• Administer the vaccine intramuscularly (IM) in the deltoid area.
• Do not administer subcutaneously (SC) or intra-dermally.
• No need to aspirate before injecting; no major blood vessels in deltoid area
• Apply plaster to injection site.
• For patients on anticoagulation, with bleeding disorders or low platelet counts, ask patient (or next of
kin) to press firmly at the injection site for 5 minutes, without rubbing.PCC
Post-vaccination
Post Vaccination Care
• Observe vaccine recipients on-site for 30 minutes for vaso-vagal reactions, fainting,
anaphylaxis, or severe allergic reactions.
• Vital signs do not need to be routinely checked. Advise recipients to inform staff if they
experience any symptoms suggesting allergic reactions.
• Give vaccine recipients a Vaccination Card to document the COVID-19 vaccine received
(date, vaccine name, dose 1 or 2), and the Vaccine Information Sheet (VIS).
• Advise vaccine recipients about potential side effects and how to manage symptoms and go
to A&E if symptoms worsen, persist or new and serious problems emerge.
• Vaccine recipients should be reassured that most symptoms will resolve within 2-3 days,
and symptomatic treatment for injection site pain, myalgia or fever can be taken, such as
paracetamol 1-2 tablets every 6 hours as needed (unless they have an allergy to
paracetamol).PCC
3. Management of adverse reactions Post-vaccination
Anaphylaxis & Vaccination
• Anaphylaxis after vaccination is generally very rare, approx. 1.3 per million
doses of influenza vaccines
• However, anaphylactic reactions to the Pfizer COVID-19 vaccine have been
reported overseas and locally
• Treatment for severe allergic reactions must be immediately available in
case of anaphylaxis after giving COVID-19 vaccine
• E-kit and epinephrine must be accessible, and clinicians trained to respond.
• HSA currently recommends that persons who receive the Pfizer COVID-19
vaccine be observed for 30 minutes post-vaccination.PCC
Post-vaccination
Recognising Anaphylaxis
Onset of 2 out of 3 of the following:
1. Acute onset mucocutaneous symptoms
• Flushing, pruritus, urticaria, angioedema – look out especially for swelling of lips, tongue and
uvula
2. Respiratory symptoms and signs
• Wheezing, stridor, hypoxia, shortness of breath, sensation of throat tightness and hoarse voice
3. Symptoms and signs of hypotension
• Fainting, dizziness, confusion, SBP < 90mmHg or DBP < 60mmHg within minutes to several hours
post-vaccination
• Some persons may also present with gastrointestinal symptoms (crampy abdominal pain, nausea,
vomiting).
• When anaphylaxis occurs after the administration of vaccine, patients generally develop symptoms
within 30 minutes, although the onset may rarely be delayed for up to several hours.PCC
Post-vaccination
Managing Anaphylaxis
• Rapidly assess airway, breathing, circulation, and mental activity
• CALL for emergency medical services or 995.
• Place patient supine with feet up, unless airway obstruction or vomiting
• Adrenaline is the first-line treatment for life-threatening anaphylaxis.
• In adults, administer 0.3 mg IM dose of adrenaline (1mg/ml = 1:1000 dilution) using a syringe, pre-filled
syringe or autoinjector in the mid-outer thigh. Maximum adult dose is 0.5 mg per dose
• Epinephrine dose may be repeated every 5-15 minutes as needed to control symptoms while waiting for
emergency medical services.
• Antihistamines and bronchodilators can be given after epinephrine.
• Because anaphylaxis may recur, patient should be monitored in a medical facility for several hours, even after
all symptoms have resolved completely.
• Advise patient NOT to receive any more doses of the same vaccine.
• Any severe adverse effects that occur after COVID-19 vaccination, including anaphylaxis, must be reported to
HSA.
Please refer to MOH Circular No. 68/2021 (2 Jun 2021) for detailed guidance,
including management for adolescents.
(“REVISED GUIDELINES ON THE MANAGEMENT OF ANAPHYLAXIS AND SEVERE
ALLERGIC REACTIONS AFTER COVID-19 VACCINATION”)PCC
Post-vaccination
Adverse Event Monitoring and Reporting
• Remind vaccine recipients to monitor and inform you of any AEs experienced that may be associated
with the vaccine.
• To facilitate HSA’s safety monitoring, healthcare professionals are required to specify the brand name
and batch number of the vaccine administered when submitting the notification on COVID-19
vaccinations to the National Immunisation Registry as well as HSA.
• Report any suspected Serious Adverse Events (SAEs)/Adverse Events of Special Interests (AESIs)
as soon as possible.
• All fatal and life-threatening SAEs/AESIs that happened within the first 30mins of observation
post-vaccination (e.g. Anaphylaxis) should be reported to HSA once the patient has been managed
and no longer than 3 hours.
• All other fatal and life-threatening events are to be reported as soon as possible, within 24hours.
• All other SAEs and AESIs are to be reported within 48hours.Other PCC Considerations for Adolescents (12-15yo) considerations • Use of Pfizer-BioNTech COVID-19 Vaccine in adolescents aged 12 to 15 years has been approved by HSA. • Same dosing regimen as that for adults. • Ongoing Phase III clinical trials (C4591001) have demonstrated 100% Vaccine Efficacy (VE) in Adolescents aged 12-15 years old, compared to 95% VE in adults • The safety profile of the vaccine in adolescents was characterised by reactogenic events which were similarly observed in the older age groups, although the incidences were slightly higher for injection site pain, fatigue, headache, chills and fever. • Overall, comparable Adverse Event (AE) profile of the vaccine in adolescents to that observed in adults. • Common hypersensitivity reactions include: Rash (0.3%), Urticaria (0.2%), Lip/Mouth Swelling (0.1%) • No reported cases of severe allergic reactions or anaphylaxis
Other PCC
Myocarditis and pericarditis following COVID-19 vaccination considerations
• While further studies and investigations are on-going, currently available data suggests that there may be a very
small risk of myocarditis and pericarditis after the second dose of an mRNA vaccine, particularly in young men.
• As a precaution, and in line with Expert Committee on COVID-19 Vaccination (EC19V) recommendations, doctors
should advise vaccinated persons, in particular adolescents and younger men aged less than 30 years old, to
avoid strenuous physical activity for one week after their first and second dose. During this time, they should
seek medical attention promptly if they develop chest pain, shortness of breath or abnormal heartbeats.
• Medical practitioners should exercise a heightened vigilance when assessing persons who have been recently
vaccinated with the mRNA COVID-19 vaccines and to clinically manage accordingly.
• Common symptoms of myocarditis and pericarditis include chest pain, shortness of breath and palpitations.
• As non-specific cardiac symptoms such as palpitations and non-cardiac chest pain are very common, the simple
presence of a non-specific cardiac symptom should not be the basis for deferring the second dose.
• Only cases diagnosed with myocarditis should be deferred subsequent COVID-19 vaccine doses and cleared by
a cardiologist.
• Doctors should assess and manage as per reasonable clinical care, and make appropriate referrals only
where clinical features substantiate a likely diagnosis of myocarditis.
• Doctors can consider advising patients to abstain from strenuous physical activity for a longer period if there is no
strong clinical suspicion for myocarditis but wish to be cautious.
Please refer to MOH Circular No. 78/2021 (12 Jun 2021) & 78A/2021 (6 July 2021) for more information.
(“MYOCARDITIS AND PERICARDITIS FOLLOWING mRNA COVID-19 VACCINATION ”)PCC
Advisory to avoid strenuous activities one week post vaccination (particularly for
adolescents and younger men aged less than 30 years old)
32PCC
4. Key takeaways
• The Pfizer/Comirnaty COVID-19 vaccine is highly effective & safe.
• Follow guidance for dilution, dosage, and safe vaccine administration, and post-vaccination care.
• Vaccine in a multi-dose vial, with at least 5 doses.
• Refrigerated shelf-life is 31 days → check expiry date.
• Once diluted, use within 6 hrs; discard unused vaccine
• Observe for 30 min post-vaccination.
• Be alert for anaphylaxis or severe allergic reaction (rare)
• Advise patients that symptoms usually improve in 2-3 days
• Remind patients to come back for Dose #2.
33Part 3iii Vaccine Planning and Ordering [CSOG, AIC]
SRMD
Ordering of Vaccine and Medical Supplies (1)
• Clinics to send completed order form via email to Zuellig Pharma at
SGZPSCSOrdersMailbox@zuelligpharma.com and copy MOH at
MOH_SRMD_Supply@moh.gov.sg
• Clinics should note the cut-off time for order and expected delivery when requesting for top-up of
vaccine and medical supplies
35SRMD
Ordering of Vaccine and Medical Supplies (2)
• Vaccines will be thawed to 2˚C to 8˚C by the logistic vendors before they are sent to
clinics.
• All delivery will be at 2˚C to 8˚C for ease of handling.
• Vaccines should be stored at 2˚C to 8˚C at clinics. The shelf life of the vaccines after
thawing to 2˚C to 8˚C is up to 31 days.
• MOH will supply ~5 days worth of vaccines
• Vaccines come in multi-dose vials that need to be reconstituted.
• Open vials to be discarded after 6 hours.
• Individuals should be given the SAME brand of vaccine for the 2-dose regimen taken
~21 days apart.
36SRMD/AIC
Sample of Vaccine Defect
Keep the vial and escalate incident report to MOH VOC at 91157048 / 91553887 or Incident Reporting via
FormSG and inform your AIC COVID Ops Manager.
37SRMD
Vaccination Supplies
Vaccination Supplies
Syringes and needles Syringe 3ml For reconstitution/dilution
Needles 21G, 1½“
Needles 23G, 1“ For vaccination
Needles 25G, 1”
Needles 21G, 1½“
Syringe 1ml
Other consumables Alcohol swabs, 100's For vaccination
Sharp Collectors 7.6L
• Clinics may procure other medical supplies for vaccination from your usual sources of supply.
• Needles, syringes, swabs and sharp collectors are available for order from Zuellig Pharma if
needed.
38AIC
First Load of Vaccine and Medical Supplies will be sent to your clinic
To support the tight execution of this operation, MOH/AIC has made special provision to support the clinics with
one-off support below. You will receive by Monday afternoon and you should be ready for Wed execution.
(1) “Start Up” Load (2) Oxygen Set from ALPS
- Vaccines
- Consumables
- Collaterals (Vaccination Forms, Vaccination Info Booklet, Vaccination Cards)
[Pfizer-BioNTech/Comirnaty 1 vial = 6
Item Description doses]
Request Qty (#vials)
Pfizer-BioNTech/Comirnaty COVID-19 Vaccine 6 doses 1 vial 20
Item Description Request Qty (number of boxes)
0.9% Sodium Chloride for Injection, 20ml
1 box of 20 vials 2
(1 box of diluent is sufficient for 20 vials of vaccine or 100 doses of vaccine)
Needles - 21G 1½" (box of 100's) for dilution 1
Needles - 23G 1" (box of 100's) for injection 1
Needles - 25G 1" (box of 100's) for injection 1
Syringe 1ml (box of 100's) for injection 2
Syringe 3ml (box of 100's) for dilution 1
Sharp Collector 7.6L 1
Alcohol swabs box of 200's 1
39AIC
AIC Account Managers
CLINIC NAME AIC ACCOUNT MANAGER
EXCEL FAMILY CLINIC Chee Hui Fen
PARKWAY SHENTON MEDICAL GROUP (HEARTLAND MALL) 9017 2406
SHENTON MEDICAL GROUP (YISHUN) Hui.fen.chee@aic.sg
TRUCARE MEDICAL AND SURGERY
HK FAMILY CLINIC & SURGERY PTE LTD
ONECARE CLINIC YISHUN Jas Lek
ACUMED MEDICAL GROUP (WOODLANDS) 8869 4251
ACUMED MEDICAL GROUP (YUNG KUANG ROAD) Jas.lek@aic.sg
FRASER MEDICAL CENTRE
SATA COMMHEALTH MEDICAL CENTRE Jessie Ong
RAFFLESMEDICAL (RAFFLES HOSPITAL) 9011 4026
RAFFLESMEDICAL (RAFFLES CITY SHOPPING CENTRE) Jessie.ong@aic.sg
PANCARE MEDICAL CLINIC
YANG & YAP CLINIC AND SURGERY (PTE LTD) Patrick Zheng
/ DR YANG ING HONG MEDICAL AND AESTHETIC CLINIC 9826 3794
BEDOK MEDICAL CENTRE patrick.zheng@aic.sg
DAYSPRING MEDICAL CLINIC (TAMPINES)
JOY FAMILY CLINIC
YIM CLINIC Samantha Goh
NORTHEAST MEDICAL GROUP (TAMPINES) 9783 1540
A MEDICAL CLINIC Samantha.goh@aic.sg
TAYKA FAMILY MEDICAL CLINIC
Samantha Lim
THE TENTERAM CLINIC 8428 1295
Samantha.lim@aic.sg
40CSOG
Processes for NAS New Slots Opening
1 4 5 6
D – 1 Week (Tue) (Wed) (Thu) (Fri) (Mon)
(Thursday)
AIC send the clinic’s slot AIC to submit
AIC will verify
opening request to SOT consolidated
SOT to update NAS, followed with PHPCs
by 9am and keeping requests to
by OGP to update on system that their slots
PPP in the loop SOT by 12pm
with confirmation of slots and are opened.
inform AIC that slots are
2 opened latest by Friday
PPPP to approve and
inform SOT to proceed by
Thursday, noon. Note: ▪ New Window slot opening period is fortnightly Friday.
▪ If Friday is a Public Holiday, Thursday will be the operation date.
3 ▪ Ad Hoc request will be subject to case by case basis.
SOT to send working file ▪ Any amendment or Ad Hoc request will be from AIC to PPPP
to AIC by Fri 12pm ▪ PPPP will sort it out with SOTPart 3iv Reporting Requirements [CSOG]
CSOG
Incident Reporting
Clinics must report any incidents which may affect or disrupt the smooth running of vaccination operations to MOH
VOC at 91157048 / 91553887 and a written report via FormSG as soon as possible within 3 hours of incident.
Please notify your AIC account manager of the incident so that they can support you with the incident management
44CSOG
Reporting Requirements
Daily Site Reps
45CSOG
Reporting Requirements
46CSOG
Reporting Requirements
Document Attachment
Daily reporting requirements
(Annex I) Annex I - Daily
reporting requirements (for All Other Sites).pptx
FormSG link:
https://go.gov.sg/dvsr
47Part 3v Other Ops Requirements [CSOG, AIC]
AIC
Prevailing Eligibility Criteria for Walk-Ins/ Soakers
• COVID-19 vaccination is free to all Singaporeans and long-term residents in Singapore.
• This includes:
i. Permanent Residents
ii. Employment Pass holders
iii. S-Pass holders
iv. Work Permit holders
v. Foreign Domestic Workers
vi. Dependents Pass
vii. Student Pass holders
viii. Long-Term Visit Pass holders
• All individuals who are eligible to make appointments through the National Appointment
System will be eligible for fully-subsidised vaccinations.
49AIC
COVID-19 Vaccination Subsidy
• MOH will reimburse participating PHPCs $35 for each actualised COVID-19 vaccination
dose. GST will be absorbed for patients for these visits and GST-registered PHPC clinics
will be able to claim GST from MOH.
• PHPCs will not be allowed to charge eligible patients any copayment for the
administration as well as the cost of the COVID-19 vaccinations.
• If the patient requires medications and investigations for treatment of other medical
conditions in the same visit, clinics can make a CHAS claim for the medication and
investigations components if applicable, but should not charge patient for a separate
CHAS Acute/Chronic consultation in such a scenario.
50PART 4 Demo and Briefing on PRPP Vaccination Module [IHiS]
PART 5 Q&A
THANK YOU!
You can also read
